FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2267064429> ?p ?o ?g. }

• W2267064429 endingPage "7" @default.
• W2267064429 startingPage "923" @default.
• W2267064429 abstract "We developed an original in vitro model dedicated to the exploration of molecular pharmacology of the new oral fluoropyrimidine capecitabine (Xeloda). More specifically, in this report, we investigated whether apoptosis induced by capecitabine was mediated by the Fas/FasL system. To achieve this goal, a specific in vitro coculture model mixing hepatoma and human colorectal cell line was used. A bystander effect was observed between HepG2 and LS174T cells treated with capecitabine. Besides this, Xeloda showed a 7-fold higher cytotoxicity and markedly stronger apoptotic potential in thymidine phosphorylase (TP)-transfected LS174T-c2 cells. The striking enhancement of thymidylate synthase inhibition that we observed in cells with high TP activity was most probably at the origin of the potentiation of capecitabine antiproliferative efficacy. In addition, this increase of sensitivity was accompanied by a strong overexpression of the CD95-Fas receptor on the cell surface. Both Fas and FasL mRNA expression were triggered after exposing TP+ cells to the drug. This implication of Fas in Xeloda-induced apoptosis was next confirmed by using antagonistic anti-Fas and anti-FasL antibodies that proved to reverse capecitabine antiproliferative activity, thus highlighting the key role that Fas could play in the optimization of an antitumor response to fluoropyrimidine drugs. Our data, therefore, show that TP plays a key role in the capecitabine activity and that the Fas/FasL system could be considered as a new determinant for Xeloda efficacy." @default.
• W2267064429 created "2016-06-24" @default.
• W2267064429 creator A5001285997 @default.
• W2267064429 creator A5024361845 @default.
• W2267064429 creator A5030959395 @default.
• W2267064429 creator A5032850423 @default.
• W2267064429 creator A5034793463 @default.
• W2267064429 creator A5040417005 @default.
• W2267064429 creator A5043823431 @default.
• W2267064429 creator A5054551100 @default.
• W2267064429 creator A5064835150 @default.
• W2267064429 creator A5088425379 @default.
• W2267064429 date "2002-09-01" @default.
• W2267064429 modified "2023-10-18" @default.
• W2267064429 title "Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas." @default.
• W2267064429 cites W1541662499 @default.
• W2267064429 cites W1572569028 @default.
• W2267064429 cites W1599036931 @default.
• W2267064429 cites W1849818006 @default.
• W2267064429 cites W1928936189 @default.
• W2267064429 cites W1971683915 @default.
• W2267064429 cites W1991470369 @default.
• W2267064429 cites W1993875123 @default.
• W2267064429 cites W2019908607 @default.
• W2267064429 cites W2076435358 @default.
• W2267064429 cites W2087288637 @default.
• W2267064429 cites W2090941375 @default.
• W2267064429 cites W2120064876 @default.
• W2267064429 cites W2124843507 @default.
• W2267064429 cites W2135955947 @default.
• W2267064429 cites W2137194656 @default.
• W2267064429 cites W2145684092 @default.
• W2267064429 cites W2149289168 @default.
• W2267064429 cites W2155421004 @default.
• W2267064429 cites W2164578725 @default.
• W2267064429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12481413" @default.
• W2267064429 hasPublicationYear "2002" @default.
• W2267064429 type Work @default.
• W2267064429 sameAs 2267064429 @default.
• W2267064429 citedByCount "8" @default.
• W2267064429 countsByYear W22670644292015 @default.
• W2267064429 countsByYear W22670644292017 @default.
• W2267064429 countsByYear W22670644292022 @default.
• W2267064429 crossrefType "journal-article" @default.
• W2267064429 hasAuthorship W2267064429A5001285997 @default.
• W2267064429 hasAuthorship W2267064429A5024361845 @default.
• W2267064429 hasAuthorship W2267064429A5030959395 @default.
• W2267064429 hasAuthorship W2267064429A5032850423 @default.
• W2267064429 hasAuthorship W2267064429A5034793463 @default.
• W2267064429 hasAuthorship W2267064429A5040417005 @default.
• W2267064429 hasAuthorship W2267064429A5043823431 @default.
• W2267064429 hasAuthorship W2267064429A5054551100 @default.
• W2267064429 hasAuthorship W2267064429A5064835150 @default.
• W2267064429 hasAuthorship W2267064429A5088425379 @default.
• W2267064429 hasConcept C121608353 @default.
• W2267064429 hasConcept C123321153 @default.
• W2267064429 hasConcept C126322002 @default.
• W2267064429 hasConcept C185592680 @default.
• W2267064429 hasConcept C190283241 @default.
• W2267064429 hasConcept C202751555 @default.
• W2267064429 hasConcept C2777909004 @default.
• W2267064429 hasConcept C2780456651 @default.
• W2267064429 hasConcept C3031857 @default.
• W2267064429 hasConcept C31573885 @default.
• W2267064429 hasConcept C502942594 @default.
• W2267064429 hasConcept C526805850 @default.
• W2267064429 hasConcept C54009773 @default.
• W2267064429 hasConcept C54355233 @default.
• W2267064429 hasConcept C55493867 @default.
• W2267064429 hasConcept C66008609 @default.
• W2267064429 hasConcept C71924100 @default.
• W2267064429 hasConcept C81885089 @default.
• W2267064429 hasConcept C86803240 @default.
• W2267064429 hasConcept C98274493 @default.
• W2267064429 hasConceptScore W2267064429C121608353 @default.
• W2267064429 hasConceptScore W2267064429C123321153 @default.
• W2267064429 hasConceptScore W2267064429C126322002 @default.
• W2267064429 hasConceptScore W2267064429C185592680 @default.
• W2267064429 hasConceptScore W2267064429C190283241 @default.
• W2267064429 hasConceptScore W2267064429C202751555 @default.
• W2267064429 hasConceptScore W2267064429C2777909004 @default.
• W2267064429 hasConceptScore W2267064429C2780456651 @default.
• W2267064429 hasConceptScore W2267064429C3031857 @default.
• W2267064429 hasConceptScore W2267064429C31573885 @default.
• W2267064429 hasConceptScore W2267064429C502942594 @default.
• W2267064429 hasConceptScore W2267064429C526805850 @default.
• W2267064429 hasConceptScore W2267064429C54009773 @default.
• W2267064429 hasConceptScore W2267064429C54355233 @default.
• W2267064429 hasConceptScore W2267064429C55493867 @default.
• W2267064429 hasConceptScore W2267064429C66008609 @default.
• W2267064429 hasConceptScore W2267064429C71924100 @default.
• W2267064429 hasConceptScore W2267064429C81885089 @default.
• W2267064429 hasConceptScore W2267064429C86803240 @default.
• W2267064429 hasConceptScore W2267064429C98274493 @default.
• W2267064429 hasIssue "11" @default.
• W2267064429 hasLocation W22670644291 @default.
• W2267064429 hasOpenAccess W2267064429 @default.
• W2267064429 hasPrimaryLocation W22670644291 @default.

• next